Abstract
In 2006, the cyclic lipopeptide antibiotic daptomycin received FDA approval for the treatment of right-sided infective endocarditis (RIE) based on the results of one of the largest infective endocarditis trials (JW Infect Dis Aug 16 2006). Since then, more patients have been treated for RIE and also (off label) for left-sided infective endocarditis (LIE). Researchers recently published treatment results for 378 such cases that had been …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
